Home › Conferences › ENA
EORTC-NCI-AACR Symposium on Molecular Targets 2026
EORTC-NCI-AACR Symposium on Molecular Targets 2026 takes place November 18 to 20, 2026 in Barcelona, ES.
Nov 18-20, 2026 · Barcelona, ES · Early-phase oncology.
DatesNov 18-20, 2026
LocationBarcelona, ES
Therapeutic focusEarly-phase oncology
Biotech presenters sourced2
Organiserevent.eortc.org
Biotech presenters
APRE
APR-1051 (WEE1); oral · source
ACESOT-1051 Phase 1 (NCT06260514); session 2026-11-20
ERASERAS-0015; oral · source
AURORAS-1 Phase 1; session 2026-11-20
Each presenter is sourced to the company's own filing or release naming this meeting; this is not the organiser's programme, and abstract titles are embargoed until the organiser publishes them.
About · Corrections · Changelog · Glossary · Methodology
Not affiliated with ENA or its organizer. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.
© 2026 pdufa.bio. All rights reserved.
Not affiliated with ENA or its organizer. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.
© 2026 pdufa.bio. All rights reserved.
What presenting companies' shares did, across the whole study
Across 1,425 presentations at major medical meetings from 2017 to 2026, the median presenting company's stock moved −0.03% in the 30 trading days before the meeting (49.8% rose) and −1.59% in the 5 trading days after (39.4% rose). Small caps: +2.75% before (n=298); nano caps: −7.86% (n=108). The middle half of all presenters ranged from −10.41% to +13.58%. The study is anchored on the meeting start date, not on the abstract release; the true catalyst may be earlier. This measures what happened; it is not a forecast for any company. Full study, with the method and its limits.
How ENA stocks have traded historically
Median share-price move around a presentation, measured across 23 ENA presentations in our study (2017-2026).
30 days before+0.16% 52% rose · n=23
10 days before-0.81% 48% rose · n=23
Presentation day+0.20% 65% rose · n=23
5 days after-2.93% 35% rose · n=23
10 days after-2.10% 44% rose · n=23
Read the whole row, not just the first line: across this study stocks have drifted up into these meetings and down out of them, and the effect is largest in the smallest companies. Medians are shown because a handful of large moves pulls an average away from the typical case. This is a historical distribution for a cohort of companies, not a forecast for any single company, and not investment advice. Methodology and the full study.
FAQ
When is ENA 2026?
EORTC-NCI-AACR Symposium on Molecular Targets 2026 runs November 18-20, 2026 in Barcelona, ES. The date comes from the organiser's own announcement; check the organiser's site for the final programme.
Which biotech companies are presenting at ENA 2026?
From company filings and releases we have sourced 2 presenter commitments for this edition: APRE, ERAS. This is not the organiser's programme -- only presentations companies have themselves announced, each linked to its filing on the conferences page.
How do biotech stocks typically trade around ENA?
In our study of 23 ENA presentations (2017-2026), the median stock moved -0.81% over the 10 trading days before the presentation (48% of them rose), +0.20% on the day itself, and -2.93% over the 5 trading days after. The pattern across the whole study is a drift up into these meetings and down out of them, strongest in the smallest companies. That is a historical distribution for a cohort, not a prediction for any one company, and not investment advice.
Why do medical conference dates matter for biotech stocks?
Trial results are often presented first at medical meetings, so a company's announced presentation is a dated, public catalyst. We publish a study of how biotech stocks have historically traded into conference presentations on the research page; it is historical measurement, not a prediction, and none of this is investment advice.